Retatrutide availability and current status is a topic of growing interest among patients, clinicians, and researchers following promising early clinical trial results. Developed by Eli Lilly, retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors — a novel mechanism that distinguishes it from existing licensed weight management medicines. As of mid-2025, retatrutide has not received marketing authorisation in the UK, EU, or US, and remains accessible only through authorised clinical trials. This article explains where retatrutide currently stands, what the UK regulatory pathway looks like, and what licensed alternatives are available now.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, increase energy expenditure, and improve metabolic control.

Retatrutide is an investigational injectable medicine being developed by Eli Lilly and Company for the treatment of obesity and type 2 diabetes. It belongs to a novel class of agents known as triple agonists, meaning it simultaneously activates three distinct hormone receptors:

• GLP-1 (glucagon-like peptide-1) — stimulates insulin secretion, reduces appetite, and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) — enhances insulin release and may improve fat metabolism

• Glucagon receptor — increases energy expenditure and promotes fat breakdown (lipolysis). It is worth noting that glucagon receptor activation can also increase hepatic glucose output; within retatrutide's triple-agonist design, this effect is thought to be counterbalanced by concurrent GLP-1 and GIP activity, though this remains under investigation in ongoing trials.

This triple mechanism distinguishes retatrutide from existing licensed treatments such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GLP-1/GIP agonist). Based on early-phase clinical data, retatrutide is designed to produce a pronounced reduction in body weight and improved metabolic control; however, no direct head-to-head trials comparing retatrutide with licensed agents have been completed, and any comparative efficacy conclusions remain hypothesis-generating at this stage.

In phase 2 trial data published in The New England Journal of Medicine (2023), retatrutide demonstrated substantial weight loss in adults with obesity — with some participants losing over 20% of their body weight over approximately 48 weeks. The drug is administered as a once-weekly subcutaneous injection, similar in delivery to other agents in its class.

Its side-effect profile in trials has broadly mirrored that of other incretin-based therapies, with nausea, vomiting, diarrhoea, and constipation being the most commonly reported adverse effects, particularly during dose escalation. As with other medicines in this class, potential class-related risks — including gallbladder events, pancreatitis, and small increases in resting heart rate — are being evaluated in ongoing studies. Long-term safety data are still being gathered, and the full safety profile of retatrutide has not yet been established.

Anyone who experiences a suspected side effect from any medicine — including those received within a clinical trial — is encouraged to report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Current Regulatory Status in the UK and Globally

As of mid-2025, retatrutide has no marketing authorisation in the UK, EU, or US; it is only accessible through authorised clinical trials and is not available for routine prescribing.

As of mid-2025, retatrutide has not received marketing authorisation in the United Kingdom, the European Union, or the United States. It remains an investigational medicinal product (IMP), meaning it is not licensed for routine clinical use in any country and is currently only accessible to patients enrolled in authorised clinical trials.

In the United States, the Food and Drug Administration (FDA) has not granted approval for retatrutide. Eli Lilly is progressing the drug through its phase 3 clinical trial programme (the TRIUMPH trials), which are required to generate the pivotal data needed to support a regulatory submission. The precise timing of any marketing application has not been publicly confirmed; regulatory submissions may proceed on a rolling basis depending on data availability and FDA guidance.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for granting marketing authorisations following the UK's departure from the European Medicines Agency (EMA) framework. The MHRA operates its own independent review process, and no application or early access designation for retatrutide has been publicly announced. Similarly, the European Medicines Agency (EMA) has not listed retatrutide as a medicine under active evaluation for marketing authorisation.

Because retatrutide is not licensed in the UK, it is not available for routine prescribing through NHS or private channels. Legitimate access is limited to participation in authorised clinical trials or, if granted, MHRA early access mechanisms such as the Early Access to Medicines Scheme (EAMS) — neither of which has been announced for retatrutide at this time. Any product claiming to be retatrutide sold outside of an authorised clinical trial setting should be treated with significant caution, as it would be unlicensed and potentially unsafe.

This information reflects the position as of mid-2025. Regulatory status can change; readers are advised to check the MHRA, EMA, and FDA websites for the most current information.

Where Retatrutide Stands in Clinical Trials

Retatrutide is currently in phase 3 evaluation through Eli Lilly's TRIUMPH trial programme, following phase 2 results showing up to 24.2% body weight loss over 48 weeks.

Retatrutide has progressed through phase 1 and phase 2 clinical trials with encouraging results, and is currently undergoing phase 3 evaluation through Eli Lilly's TRIUMPH clinical trial programme. Phase 3 trials are the large-scale, randomised controlled studies required to establish efficacy and safety across diverse patient populations before a regulatory submission can be made.

The phase 2 trial published in The New England Journal of Medicine in 2023 enrolled adults with obesity without type 2 diabetes and demonstrated dose-dependent weight loss of up to 24.2% of body weight at the highest dose over 48 weeks — results that attracted considerable scientific and media attention. Improvements in cardiometabolic markers, including blood pressure, lipid profiles, and glycaemic parameters, were also observed. Separate phase 2 data in adults with type 2 diabetes have been presented at scientific conferences; readers should consult primary sources for details of those populations and outcomes.

The ongoing phase 3 TRIUMPH trials are evaluating retatrutide across several key populations, including:

• Adults with obesity (BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities)

• Adults with type 2 diabetes

• Patients with cardiovascular risk factors — the inclusion of a dedicated cardiovascular outcomes component is subject to confirmation via registered trial records; readers are encouraged to check ClinicalTrials.gov for current NCT identifiers and study designs within the TRIUMPH programme.

These trials are expected to generate the robust, long-term safety and efficacy data required for regulatory review. Phase 3 trials typically take several years to complete, and results from the TRIUMPH programme are anticipated broadly in the 2025–2027 timeframe based on estimated completion dates registered on ClinicalTrials.gov, though this is subject to change. Until these trials conclude and data are submitted to regulators, the clinical development of retatrutide remains ongoing and its ultimate approval is not guaranteed.

MHRA and NICE Approval Pathway Explained

Before reaching NHS patients, retatrutide must first obtain MHRA marketing authorisation, then undergo a NICE technology appraisal; NHS England must fund a positively appraised medicine within 90 days.

Understanding how a new medicine reaches NHS patients in the UK helps contextualise the timeline for retatrutide. The process involves two distinct but sequential stages: regulatory approval by the MHRA, followed by health technology assessment (HTA) by the National Institute for Health and Care Excellence (NICE).

Step 1 — MHRA Marketing Authorisation: Before any medicine can be routinely prescribed in the UK, the manufacturer must submit a comprehensive dossier of clinical trial data to the MHRA. The MHRA assesses the drug's quality, safety, and efficacy. If satisfied, it grants a marketing authorisation (formerly known as a product licence). In some circumstances, a conditional marketing authorisation may be granted where the benefit–risk balance is positive but further confirmatory data are still awaited.

The MHRA also operates an Innovative Licensing and Access Pathway (ILAP), designed to accelerate access for promising medicines with significant unmet need. Retatrutide could potentially be considered for this route given its novel mechanism, though no ILAP designation has been announced and eligibility would need to be assessed formally by the MHRA.

Step 2 — NICE Technology Appraisal: Once licensed, NICE evaluates whether the medicine represents value for money for the NHS, using a cost-effectiveness framework typically expressed as cost per quality-adjusted life year (QALY). NICE can begin its appraisal process before a licence is granted, meaning the two stages may overlap. Following a positive final NICE Technology Appraisal (TA), NHS England is required by statute to fund the medicine within 90 days. The overall appraisal process varies in duration depending on the complexity of the evidence and the appraisal route used.

For obesity medicines specifically, NICE has historically applied criteria around BMI thresholds (in kg/m²), comorbidities, and specialist service settings. Given that existing agents such as semaglutide and tirzepatide have faced NHS access constraints due to supply and commissioning limitations, the pathway for retatrutide — even after approval — may involve phased or restricted rollout.

Patients in Scotland, Wales, and Northern Ireland should note that medicines are assessed separately by the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland, respectively, meaning availability may differ across the devolved nations. Patients should not assume that MHRA approval automatically translates to immediate NHS availability in any part of the UK.

When Might Retatrutide Become Available in the UK?

The earliest realistic timeline for UK availability is 2028 or later, following anticipated phase 3 data in 2025–2026, a potential MHRA submission in 2026–2027, and subsequent NICE appraisal.

Predicting the precise timeline for retatrutide's availability in the UK involves considerable uncertainty, and any estimates should be treated as indicative rather than definitive. Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows:

• 2025–2026: Completion of key phase 3 TRIUMPH trial data

• 2026–2027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel)

• 2027–2028: Possible MHRA marketing authorisation, subject to satisfactory review

• 2028 onwards: NICE technology appraisal and potential NHS commissioning decision

These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations. It is also possible that retatrutide could receive a conditional marketing authorisation or benefit from the MHRA's ILAP or Early Access to Medicines Scheme (EAMS) if it demonstrates exceptional benefit in a population with high unmet need, though no such designation has been announced.

Following any MHRA licence, it is worth noting that private prescribing could in principle occur before a NICE commissioning decision is reached, subject to medicine availability and supply — though this would not constitute NHS-funded access.

Patients who are interested in accessing retatrutide before potential approval may wish to explore whether they are eligible for clinical trial participation. The NIHR Be Part of Research platform (bepartofresearch.nihr.ac.uk) and the ClinicalTrials.gov database list ongoing studies, and some UK sites may be participating in the TRIUMPH programme. Eligibility criteria vary, and participation should always be discussed with a qualified healthcare professional.

It is strongly advised that patients do not seek retatrutide from unregulated online sources, as unlicensed products carry serious risks including contamination, incorrect dosing, and unknown safety profiles.

Readers are advised to check the MHRA and NICE websites regularly, as the regulatory and commissioning position may change.

Existing Licensed Alternatives Available on the NHS

Licensed weight management medicines currently available in the UK include semaglutide (Wegovy), tirzepatide (Mounjaro), orlistat, liraglutide (Saxenda), and naltrexone/bupropion (Mysimba), subject to eligibility criteria.

Whilst retatrutide remains in development, several effective, licensed treatments for obesity and type 2 diabetes are already available in the UK. Patients should discuss these options with their GP or specialist when considering weight management.

Licensed weight management medicines in the UK include:

• Orlistat (Xenical; Alli at lower dose) — a lipase inhibitor that reduces dietary fat absorption. Available on NHS prescription and over the counter at lower doses. NICE recommends it as an adjunct to lifestyle intervention in adults with BMI ≥28 kg/m² (with associated risk factors) or ≥30 kg/m². Refer to the current BNF monograph and NICE guidance for full prescribing criteria.

• Semaglutide 2.4 mg (Wegovy) — a once-weekly GLP-1 receptor agonist licensed specifically for chronic weight management. NICE recommended it (TA875) for use within specialist weight management services in adults meeting specific BMI and comorbidity criteria. Supply constraints have affected NHS availability; patients should check current NHS guidance for the latest position.

• Tirzepatide (Mounjaro) — a dual GLP-1/GIP agonist licensed in the UK for type 2 diabetes and, following a positive NICE technology appraisal (TA1026), recommended for weight management in eligible adults within specialist services. It represents the closest currently available agent to retatrutide in terms of mechanism. Eligibility criteria and commissioning arrangements apply; patients should confirm current availability with their specialist service.

• Liraglutide 3 mg (Saxenda) — a once-daily GLP-1 receptor agonist licensed for obesity management (NICE TA664). In clinical practice it has been largely superseded by once-weekly semaglutide, though it remains a licensed option.

• Naltrexone/bupropion (Mysimba) — a combination medicine acting on appetite-regulating pathways in the brain. NICE has appraised this medicine; patients should check current NICE guidance and local commissioning decisions for eligibility and availability.

• Setmelanotide (Imcivree) — licensed for the treatment of obesity caused by specific rare genetic conditions (including pro-opiomelanocortin [POMC] deficiency and leptin receptor deficiency). This is a highly specialist option for a defined patient group and is not a general obesity treatment.

Patients interested in pharmacological weight management should speak with their GP or a specialist obesity service, as eligibility, availability, and suitability vary. NICE guidelines and technology appraisals — including the current core obesity guideline and relevant TAs — provide the framework for prescribing decisions in England. Lifestyle intervention, including dietary modification and increased physical activity, remains the cornerstone of obesity management alongside any pharmacotherapy.

For the most up-to-date information on NHS access, eligibility criteria, and service availability, patients are encouraged to visit www.nice.org.uk and www.nhs.uk.

Frequently Asked Questions